RXi Pharma's agreement benefits ocular treatment

RXi Pharmaceuticals (Rxi) has entered into a research collaboration with the department of ophthalmo

The collaboration will focus on the application of RXi's self-delivering RNAi (sd-rxRNA) compounds for ocular diseases such as age-related macular degeneration, the leading cause of blindness in Americans over 55 years.

RXi previously presented positive data on spontaneous cellular uptake and potent activity of sd-rxRNA compounds in retinal cells. The collaboration with UMMS is expected to advance the company's therapeutic platform by evaluating the delivery and silencing activity of sd-rxRNAs in preclinical models of ocular disease.

Next Article